Wedbush Increases Vigil Neuroscience (NASDAQ:VIGL) Price Target to $24.00

Vigil Neuroscience (NASDAQ:VIGL) had its price target upped by Wedbush from $23.00 to $24.00 in a research report released on Friday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on VIGL. Guggenheim dropped their price objective on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.80.

Vigil Neuroscience Trading Up 3.6 %

Shares of VIGL opened at $3.70 on Friday. The company’s fifty day simple moving average is $3.58 and its 200-day simple moving average is $3.65. The company has a market cap of $146.70 million, a P/E ratio of -1.79 and a beta of 1.92. Vigil Neuroscience has a twelve month low of $2.47 and a twelve month high of $6.98.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.02. Analysts predict that Vigil Neuroscience will post -2.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

Several institutional investors have recently made changes to their positions in VIGL. Point72 Asset Management L.P. bought a new position in Vigil Neuroscience during the 2nd quarter worth about $5,940,000. Vanguard Group Inc. boosted its stake in shares of Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after purchasing an additional 95,276 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in shares of Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after purchasing an additional 166,442 shares in the last quarter. abrdn plc purchased a new position in Vigil Neuroscience during the third quarter valued at approximately $799,000. Finally, Renaissance Technologies LLC raised its stake in Vigil Neuroscience by 19.2% in the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.